Journal for ImmunoTherapy of Cancer (Nov 2021)
159 Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers
Abstract
No abstracts available.